the invention discloses dosage form with controlled release comprising \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438 effective amount of \u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438 active ag yente, the \u0430\u0446\u0438\u043a\u043b\u043e\u0432\u0438\u0440\u043e\u043c,for the release of approximately 12 hours of not more than approximately 90% of the active agent in the stomach juice which appears at the speed of release per the model order in the test speciesthe creation of \"the 1st kind of pharmacopoeia the united states, and its \u0441\u043e\u043b\u044e\u0431\u0438\u043b\u0438\u0437\u0430\u0442\u043e\u0440 or substance to the \u043d\u0430\u0431\u0443\u0445\u0430\u043d\u0438\u044e, or both of them, which includes (a) a pill made from on \u043b\u0438\u043c\u0435\u0440\u043d\u043e\u0439 matrix attwo biocompatible polymers by \u043a\u0430\u0440\u0431\u043e\u043f\u043e\u043b\u043e\u043c 974\u0440 and \u043f\u043e\u043b\u0438\u044d\u0442\u0438\u043b\u0435\u043d\u043e\u043a\u0441\u0438\u0434\u043e\u043c,from the \u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438 active agent and \u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438 the subsidiary substances the capsule can \u043d\u0430\u0431\u0443\u0445\u0430\u0442\u044c with high speed without destruction and in which appears to stomach juicethe volume for its retention in the stomach, by initiating a controlled release of the active agent through the ongoing controlled dissolutionas well as diffusion immediately after contact with gastric juice, or (b) \u043c\u0438\u043a\u0440\u043e\u0441\u0444\u0435\u0440\u044b \u043d\u0435\u043f\u0440\u0438\u0432\u0438\u0442\u043e\u0433\u043e \u0445\u0438\u0442\u043e\u0437\u0430\u043d\u0430 or derivative \u0445\u0438\u0442\u043e\u0437\u0430\u043d\u0430 submitted \u0442\u0438\u043e\u043b\u0438\u0440\u043e\u0432\u0430 \u043
